Moderna (NASDAQ:MRNA) Shares Gap Down – Time to Sell?

Shares of Moderna, Inc. (NASDAQ:MRNA) gapped down prior to trading on Monday . The stock had previously closed at $35.53, but opened at $33.88. Moderna shares last traded at $33.38, with a volume of 3,066,453 shares trading hands.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research reports. UBS Group decreased their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Wolfe Research assumed coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Price Performance

The stock’s fifty day simple moving average is $38.04 and its two-hundred day simple moving average is $52.46. The company has a market capitalization of $13.29 billion, a price-to-earnings ratio of -3.71 and a beta of 1.59.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 2,664 shares of company stock valued at $115,210 over the last quarter. Insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Intrinsic Value Partners LLC boosted its position in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after buying an additional 24,505 shares during the period. Banco Santander S.A. bought a new stake in Moderna during the 3rd quarter valued at $3,550,000. John G Ullman & Associates Inc. boosted its position in Moderna by 341.3% during the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after acquiring an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares in the last quarter. Finally, abrdn plc increased its holdings in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.